Phase I Trial HIPEC With Nal-irinotecan

NCT04088786 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Peritoneal Cancer
Pseudomyxoma Peritonei
Mucinous Adenocarcinoma
Mucinous Tumor
Colorectal Cancer
Gastric Cancer
Primary Peritoneal Carcinoma
Mesothelioma

Interventions

DRUG: nanoliposomal irinotecan

Sponsor

Stony Brook University

Collaborators

[object Object]
[object Object]
[object Object]